Insilico Medicine, a China-based biotech leveraging generative artificial intelligence (AI), has announced the initiation of a clinical study for its potential first-in-class PHD inhibitor, ISM5411, targeting inflammatory bowel disease (IBD).
ISM5411 is an intestinal-restricted small-molecule inhibitor developed using Insilico’s Pharma.AI platform, featuring a novel molecular framework and a unique binding mode. The ongoing Phase I clinical study (NCT06012578) aims to enroll 76 healthy participants to evaluate the safety, tolerability, pharmacokinetics, and food effects of the oral candidate drug at escalating doses. This study is currently being conducted in Australia, with plans for a global multi-center Phase Ib study to follow upon completion of the Phase Ia trial.
Insilico’s innovative approach underscores the growing intersection of AI and drug development, potentially paving the way for new therapeutic options in the management of IBD.- Flcube.com
